Literature DB >> 19610265

Severity of asthma: the role of CD25+, CD30+, NF-kappaB, and apoptotic markers.

A S Abdulamir1, H S Kadhim, R R Hafidh, M A Ali, I Faik, F Abubakar, K A Abbas.   

Abstract

OBJECTIVES: We studied the role of the regulatory T cells CD4+CD25+ (Treg) and activated CD4+CD30+ cells in the pathogenesis of asthma and their association with apoptosis and NF-kappaB in patients with mild intermittent asthma (MA), severe persistent asthma (SA), and healthy volunteers (HV).
METHODS: Peripheral blood lymphocytes (PBL) were extracted from asthmatic patients during exacerbations, and CD4+ cells were separated using Dynal beads. Immunostaining of whole PBL for NF-kappaB, Bax, and Bcl-2, and immunostaining of CD4+ cells for CD25+ and CD30+ cells were performed using immunocytochemistry.
RESULTS: Treg cells were expressed at higher levels in MA than in HV and SA (P < .05), while CD30+ T cells were expressed at higher levels in both SA and MA than in HV (P < .05), although there was no remarkable difference between SA and MA (P>.05). Levels of NF-kappaB, Bcl-2, and Bcl-2/Bax increased, whereas those of Bax decreased, progressively, from MA to SA (P < .05). NF-kappaB levels correlated directly with the Bcl-2/Bax ratio and with CD4+CD30+ cells in SA and MA, whereas CD4+CD30+ cells correlated inversely with the Bcl-2/Bax ratio.
CONCLUSIONS: Unregulated Treg cells probably return inflammatory responses to normal values during exacerbations in MA; however, expression of Treg cells was extensively diminished in SA, leading to probable loss of suppressive control over underlying immune reactions. CD4+CD30+ cells were associated with the pathogenesis of asthma but not with severity. NF-kappaB seems to be the central inflammatory factor in SA, with a remarkable loss of PBL apoptosis, diminished Treg levels, and high CD30+ cell levels that probably induce NF-kappaB, which in turn blocks the proapoptotic potential of CD30 induction itself.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19610265

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  7 in total

1.  Anti-inflammatory effects of Boletus edulis polysaccharide on asthma pathology.

Authors:  Songquan Wu; Guangli Wang; Ruhui Yang; Yubao Cui
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

2.  Effect of Lactobacillus salivarius on Th1/Th2 cytokines and the number of spleen CD4⁺ CD25⁺ Foxp3⁺ Treg in asthma Balb/c mouse.

Authors:  Xiang Yun; Yunxiao Shang; Miao Li
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

3.  Sublingual Immunotherapy for Asthma: Affects T-Cells but Does not Impact Basophil Activation.

Authors:  Olga Ciepiela; Anna Zawadzka-Krajewska; Iwona Kotuła; Frans van Overveld; Marek Kulus; Urszula Demkow
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2014-03-01       Impact factor: 1.349

Review 4.  The potential of biologics for the treatment of asthma.

Authors:  Girolamo Pelaia; Alessandro Vatrella; Rosario Maselli
Journal:  Nat Rev Drug Discov       Date:  2012-12       Impact factor: 84.694

5.  Nuclear Factor kappa B is central to Marek's disease herpesvirus induced neoplastic transformation of CD30 expressing lymphocytes in-vivo.

Authors:  Shyamesh Kumar; Dusan Kunec; Joram J Buza; Hsin-I Chiang; Huaijun Zhou; Sugalesini Subramaniam; Ken Pendarvis; Hans H Cheng; Shane C Burgess
Journal:  BMC Syst Biol       Date:  2012-09-14

6.  CD30 Is Highly Expressed in Chronic Obstructive Pulmonary Disease and Induces the Pulmonary Vascular Remodeling.

Authors:  Liang Luo; Yangli Liu; Dubo Chen; Fengjia Chen; Hai Bing Lan; Canmao Xie
Journal:  Biomed Res Int       Date:  2018-06-10       Impact factor: 3.411

7.  Prioritizing Molecular Biomarkers in Asthma and Respiratory Allergy Using Systems Biology.

Authors:  Lucía Cremades-Jimeno; María Ángeles de Pedro; María López-Ramos; Joaquín Sastre; Pablo Mínguez; Ignacio Mahillo Fernández; Selene Baos; Blanca Cárdaba
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.